NDA 020298 · Mylan
Aloprim
Allopurinol Sodium · Injection
Priority reviewOrphanLast checked: Nov 20, 2026Latest source record: Feb 17, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
May 17, 1996
Approved uses
1
Original approval plus efficacy supplements
Registered trials
209
51 Phase 3, 13 recruiting
FAERS reports
157,748
129,258 serious, 22,111 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 18, 2022.
ALOPRIM is indicated for the management of adult and pediatric patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy. ALOPRIM is a xanthine oxidase inhibitor indicated for the management of adult and pediatric patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy. ( 1 )
Mechanism: Allopurinol is a structural analogue of the natural purine base, hypoxanthine. Allopurinol and its oxypurinol metabolite inhibitor xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and of xanthine to uric acid, the end product of purine metabolism in humans. Allopurinol does not disrupt the biosynthesis of purines. The action of oral allopurinol differs from that of uricosuric agents, which lower the serum uric acid level by increasing urinary excretion of uric acid. Allopurinol reduces both the serum and urinary uric acid levels by inhibiting the...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 17, 1996 Original approval · Type 3 - New Dosage Form · priority review
1 products under this application
- ALOPRIM · ALLOPURINOL SODIUM EQ 500MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Allopurinol" as an intervention, any sponsor and status, largest first.
- Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)Pivotal-lookingCompleted
TakedaTakeda (TAK)
NCT01101035 · 6,198 participants · Start Apr 23, 2010 · Primary completion May 15, 2017
Drug: Febuxostat; Allopurinol · For: Cardiovascular Disease
Sites: Decatur, Georgia; Dunwoody, Georgia; Marietta, Georgia · 203 sites in all
- Efficacy and Safety of Oral Febuxostat in Participants With GoutPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00430248 · 2,269 participants · Start Feb 2007 · Primary completion Mar 2008
Drug: Febuxostat; Febuxostat and 1 more · For: Gout
Sites: Birmingham, Alabama; Hoover, Alabama; Hueytown, Alabama · 258 sites in all
- Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout PatientsPivotal-lookingCompleted
LG ChemIndustry
NCT05586971 · 2,202 participants · Start Mar 30, 2023 · Primary completion May 6, 2025
Drug: Tigulixostat; Allopurinol and 1 more · For: Gout; Hyperuricemia; Gout Flare and 1 more
Sites: Birmingham, Alabama; Daphne, Alabama; Mobile, Alabama · 279 sites in all
- Allopurinol Outcome StudyCompleted
Ardea Biosciences, Inc.Industry
NCT01391325 · 1,735 participants · Start Jul 2011 · Primary completion Jan 2013
Drug: Allopurinol · For: Gout
Sites: Birmingham, Alabama; Bringham, Alabama; Calera, Alabama · 173 sites in all
- Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)Pivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT00856206 · 1,315 participants · Start Mar 2009 · Primary completion Jan 2011
Drug: Rilonacept · For: Gout
Sites: Alabaster, Alabama; Mesa, Arizona; Burbank, California · 124 sites in all
- The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular RiskPivotal-lookingRecruiting
Poznan University of Medical SciencesAcademic, hospital or other
NCT05943821 · 1,116 participants (planned) · Start Sep 1, 2023 · Primary completion Jul 31, 2028
Drug: Allopurinol 200 mg; Optional intervention · For: Cardiovascular Diseases; Uric Acid
Sites: Poznan, Poland
- Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010Pivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00175019 · 1,086 participants · Start Jul 2003 · Primary completion Feb 2007
Drug: Febuxostat; Febuxostat and 1 more · For: Gout
- Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.Pivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00174915 · 1,072 participants · Start Feb 2003 · Primary completion Apr 2004
Drug: Febuxostat; Febuxostat and 3 more · For: Gout
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea8,831
- fatigue8,385
- dyspnoea8,016
- nausea7,397
- death6,985
- acute kidney injury6,871
- off label use6,806
- pyrexia6,125
- pneumonia5,754
- asthenia5,712
- anaemia5,511
- drug ineffective5,240
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,482 |
| 2005 | 2,097 |
| 2006 | 2,079 |
| 2007 | 1,811 |
| 2008 | 2,228 |
| 2009 | 2,744 |
| 2010 | 3,359 |
| 2011 | 4,397 |
| 2012 | 5,350 |
| 2013 | 5,159 |
| 2014 | 5,525 |
| 2015 | 8,242 |
| 2016 | 9,190 |
| 2017 | 9,476 |
| 2018 | 12,941 |
| 2019 | 13,166 |
| 2020 | 12,835 |
| 2021 | 11,186 |
| 2022 | 10,731 |
| 2023 | 9,249 |
| 2024 | 8,954 |
| 2025 | 9,066 |
| 2026 | 6,469 |
Recalls
1 FDA enforcement reports for this application.
May 5, 2020 · Class II · Terminated
Discoloration: Out-of-specification results for appearance obtained during routine stability testing at the end of shelf-life for the parameters Appearance and Color of Solution.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
White WB, Saag KG, Becker MA, et al. · N Engl J Med 2018 · Comparative Study, Equivalence Trial
- Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA, Schumacher HR, Wortmann RL, et al. · N Engl J Med 2005 · Clinical Trial, Phase III, Comparative Study
- Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Mackenzie IS, Ford I, Nuki G, et al. · Lancet 2020 · Multicenter Study, Randomized Controlled Trial
- Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual-Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial.
Dalbeth N, Billington K, Doyle A, et al. · Arthritis Rheumatol 2019 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Effects of Allopurinol on the Progression of Chronic Kidney Disease.
Badve SV, Pascoe EM, Tiku A, et al. · N Engl J Med 2020 · Multicenter Study, Randomized Controlled Trial
- Febuxostat for treating chronic gout.
Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Mylan
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.